Exenatide acetate | CAS:141732-76-5

We serve Exenatide acetate CAS:141732-76-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Exenatide acetate

Chemical Name:Exenatide acetate
CAS.NO:141732-76-5
Synonyms:Exenatide acetate
Exenatide
 
Physical and Chemical Properties:
Molecular Formula C186H286N50O62S
Molecular Weight 4246.62000
 
Specification:
Appearance:White to off-white powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Exenatide is a 39-amino-acid peptide, an insulin secretagogue, with glucoregulatory effects. Exenatide is a glucagon-like peptide-1 agonist (GLP-1 agonist) medication, belonging to the group of incretin mimetics. Exenatide enhances glucose-dependent insulin secretion by the pancreatic beta-cell, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying.



Contact us for information like Exenatide acetate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Exenatide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Exenatide acetate Use and application,Exenatide acetate technical grade,usp/ep/jp grade.


Related News: Massachusetts state health officials, in conjunction with Massport, local health departments, and other medical partners, have responded to prevent the spread of the virus.Furfuryl thiopropionate manufacturer Massachusetts state health officials, in conjunction with Massport, local health departments, and other medical partners, have responded to prevent the spread of the virus.Lilial supplier Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).(2R,3S)-N-Benzoyl-3-phenyl Isoserine vendor Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).Since first being reported in the city of Wuhan, where it is believed to have originated at a seafood market, the virus has not provoked unusual symptoms in people who have been diagnosed.